(Q38255277)

1 September 2017

1 reference

title

Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs (English)

1 reference

1 September 2017

1 reference

Eduardo L Franco

4

0 references

author name string

Sandra D Isidean

series ordinal

1

1 reference

1 September 2017

Joseph E Tota

series ordinal

2

1 reference

1 September 2017

Julien A Gagnon

series ordinal

3

1 reference

1 September 2017

publication date

30 September 2014

1 reference

Expert Review of Vaccines

1 September 2017

published in

1 reference

1 September 2017

volume

14

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

119-133

1 reference

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

A review of clinical trials of human papillomavirus prophylactic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Chapter 13: Current findings from prophylactic HPV vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus vaccines--immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Establishment and operation of a biorepository for molecular epidemiologic studies in Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Penile cancer: epidemiology, pathogenesis and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Genital HPV infection and related lesions in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Chapter 6: Epidemiology and transmission dynamics of genital HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The cost-effectiveness of male HPV vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The 2010 global proficiency study of human papillomavirus genotyping in vaccinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Coevolution of papillomaviruses with human populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Six-month natural history of oral versus cervical human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Prevalence of heavy smoking in California and the United States, 1965-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The role of HPV in head and neck cancer and review of the HPV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Oral sexual behaviors associated with prevalent oral human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus-related disease in men: not just a women's issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Discordance between sexual behavior and self-reported sexual identity: a population-based survey of New York City men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The cost effectiveness of human papillomavirus vaccines: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Modeling preventative strategies against human papillomavirus-related disease in developed countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Age-specific prevalence of infection with human papillomavirus in females: a global review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Age-based programs for vaccination against HPV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

cobas 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

The road ahead for cervical cancer prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV‐Infected Men: The HIPVIRG Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.964213

10.1586/14760584.2015.964213

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference